Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument by Kalbe, Elke et al.
Screening for cognitive deficits in Parkinson’s disease with the Parkinson 
neuropsychometric dementia assessment (PANDA) instrument 
 
 
Elke Kalbe a,*, Pasquale Calabrese b, Nils Kohn a, Rüdiger Hilker c, Oliver Riedel d, Hans-
Ulrich Wittchen d, Richard Dodel e, Jörg Otto f, Georg Ebersbach f, Josef Kessler a 
 
 
a Department of Neurology, University Hospital, University of Cologne, Germany 
b Department of Neurology, University Clinic, Bochum, Germany 
c Department of Neurology, Goethe University Frankfurt, Germany 
d Institute of Clinical Psychology and Psychotherapy, Technical University of Dresden, Germany 
e Department of Neurology, Philipps University Marburg, Germany 
f Neurological Hospital for Movement Disorders, Kliniken Beelitz, Germany 
  
 
 
Abstract  
 
Cognitive and affective dysfunctions are frequent but often neglected symptoms in Parkinson’s disease 
(PD). We developed the screening tool Parkinson neuropsychometric dementia assessment (PANDA) 
with five cognitive tasks and a short depression questionnaire. Healthy subjects and patients without 
cognitive impairment (PD), mild cognitive disorder (PD-MCD), or dementia (PDD) were examined. 
The cognition part had a specificity of 91% and a sensitivity of 90% for PDD and 77% for PDD plus 
PD-MCD patients. The mood questionnaire also had high sensitivity and specificity. We conclude that 
the PANDA is an economical, easy-to-use and sensitive tool to detect neuropsychological 
dysfunctions in PD patients in clinical practice.   
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1. Introduction  
 
Mental dysfunction frequently accompanies the motor symptoms in patients with Parkinson’s 
disease (PD) and ranges from subtle cognitive deficits to dementia. It has been estimated that 
20–40% of PD patients develop dementia in the course of their disease (Parkinson’s disease 
dementia, PDD), and there is recent evidence indicating that the risk of developing dementia 
increases with disease progression [1] and correlates with the neuropathologic stage in PD [2]. 
The clinical demarcation of PDD to Lewy body dementia and Alzheimer dementia is often 
difficult, and the cognitive profile in these patients is inhomogeneous. Although controversial, 
cognitive disturbances in PDD typically are thought to constitute a form of „subcortical 
dementia“ [3] which comprises a progressive dysexecutive syndrome, deficits in attention, 
memory, and visuospatial abilities. Psychiatric symptoms such as mood disturbances and 
anxiety are also frequent [4]; depressive symptoms occur in approximately half of PD patients 
[5]. Although these psychopathological features constitute an important risk factor for 
caregiver distress, nursing home placement, and decreased quality of life, they are often not 
considered in a more complex diagnostic decision and the treatment of PD patients [1].  
 
Because the diagnostic assessment of cognitive impairment, dementia, and 
psychopathological features is usually not feasible in routine care, there is a need for time-
economic, reliable, sensitive screening tools for cognitive dysfunction. Several cognitive 
screening instruments exist, for example, the Mini Mental State Examination (MMSE) [6], the 
Memory Impairment Screen (MIS) [10], the Addenbrooke’s Cognitive Examination (ACE) 
[6], or the Seven Minute Screen [7]. However, these are typically designed for „cortical“ 
types of dementia such as Alzheimer0s disease which have a neuropsychological profile 
different from „subcortical“ dementia [9] and may thus not grasp PD patients’ typical 
cognitive deficits. Furthermore, they usually do not detect dysfunctions from mild deficits up 
to severe dementia, and none of them accounts for the most frequent neuropsychiatric 
symptom in PD that may complicate the clinical picture and is important for clinical settings 
and for general practitioners, namely depression.  
 
On the basis of these considerations we developed a new brief test for PD patients—the 
Parkinson neuropsychometric dementia assessment instrument (PANDA) highlighting the 
following requirements: the test should allow for (1) an assessment of cognitive functions 
typically impaired in PD patients (2) a short (time-economic) and (3) a sensitive assessment 
of cognitive impairment and dementia in PD, and (4) it should also incorporate a screening of 
depressive symptoms as the most frequent neuropsychiatric disturbance in PD patients.  
 
In this paper we introduce the PANDA, focusing on (1) the selection of the PANDA’s 
subtests, (2) the description of the PANDA scoring procedures, and (3) the presentation of 
findings from the normation study with healthy control subjects and PD patients. (4) 
Furthermore, we compare the performance of the PANDA against the currently most used 
screening method, the MMSE.  
 
2. Methods  
 
2.1. The PANDA: rationale and selection of subtests  
 
The PANDA consists of a cognitive test part and a brief mood questionnaire. For the 
cognition part five tasks which are short and easy to administer and which assess functions 
typically affected in PD were designed on the basis of established neuropsychological test 
paradigms. The PANDA was not intended to provide a profile of single functions but rather to 
have high sensitivity to detect cognitive impairment. Thus, tasks were allowed to include a 
diversity of domains (e.g. speed of processing, executive function, and attention). These five 
tasks have been selected from an original number of eight subtests additionally including a 
Stroop interference task and another visuospatial task (mental rotation). These two tasks were 
not further considered, however, due to findings in a pilot study with 20 non-demented PD 
patients and 30 age-matched control subjects. It revealed low sensitivity (correct classification 
of control subjects) of Stroop task and low specificity (correct classification of the patients) of 
a mental rotation task (less than 55%). All tasks of the final PANDA version were well 
understood and accepted by patients and take approximately 8–10 min to administer including 
instructions and raw score analysis by the administrator. However, in a few patients with 
advanced stages of dementia and severe impairment of information processing the 
administration time went up to 20 min.  
 
(1) Word pair associate learning task with immediate and (subtest 5) delayed recall: Memory 
impairments are well documented in PD and PDD patients (overview in [1]). In contrast, to 
learning and memory dysfunction in Alzheimer’s disease which are known to be due to 
primary encoding, storage, and retrieval problems, it is suggested that PD patients’ deficits 
may largely be due to ineffective strategies in encoding and retrieval, that is, executive 
dysfunctions [8], and in fact memory impairment relates to executive function test scores in 
PDD patients [9].  
 
Word lists with immediate and delayed recall are well-established paradigms to assess verbal 
memory, and many variants exist [10]. Word pair associate learning tasks impose 
extraordinary demands on executive functions and attention as two words have to be actively 
linked to each other by mental strategies. Task difficulty can be varied depending on variables 
such as frequency or concreteness of single words as well as on semantic association between 
word pairs.  
 
Following a pilot study in which we tested different numbers of word pairs, recall trials, word 
characteristics, and relatedness of words, we selected four pairs of concrete, frequent, but 
semantically unrelated words (banana–suit, paper–frog, storm–ball, feather–scarf) for the 
PANDA. These pairs are presented three times in the immediate recall condition, each time 
followed by immediate recall after presentation of one of these words (e.g. banana–?). The 
order of the words in the recall condition is different in each trial. In the delayed recall 
condition (subtest 5) approximately 6–8 min after the immediate recall all four word pairs 
again have to be completed after presentation of one of the words. The number of correctly 
recalled words is registered. The maximal raw score is 12 for the immediate recall and 4 for 
the delayed recall condition.  
 
(2) Alternating verbal fluency task: Verbal fluency or word generation tasks are well known 
paradigms in psychometric testing [10]. They have a very high sensitivity in detecting 
cognitive impairment and also dementia, even in early stages of the disease [11–13]. This 
high sensitivity is probably due to the large spectrum of cognitive domains involved including 
attention and working memory, executive function (especially cognitive flexibility and 
strategy use), semantic memory (word retrieval), and speed of processing. Several variants of 
these tasks exist. The main principle is that subjects have to generate words in a restricted 
time (usually 1 min) and with restrictive search conditions, using either words from a 
semantic category (semantic fluency tasks, e.g. with the category animals), or words 
beginning with a specific letter (letter fluency tasks, e.g. with the letters F, A, or S), or 
alternating between categories. PD patients are significantly impaired in verbal fluency tasks, 
especially of the semantic type [14]. Furthermore, alternating fluency tasks that impose heavy 
demands upon attention, working memory, and switching ability (i.e. executive functions) 
may disproportionately be affected [14].  
 
We thus chose an alternating verbal fluency task with two semantic categories (animals and 
furniture) for the PANDA. Subjects are asked to generate as many examples of these 
categories as possible within 1 min and to switch between categories after each item. Both the 
number of correct words and switching errors are registered.  
 
(3) Visuospatial task: There is considerable evidence of visuospatial dysfunction in PD 
patients, even when tests contain few motor components [15–18]. Deficits in visual 
perception may even be among the earliest symptoms of cognitive decline in PD and seem to 
be independent of the severity of motor dysfunctions or overall intellectual impairment 
[19,20].  
 
Of two visuospatial tasks originally designed for the PANDA one was sorted out (a mental 
rotation task) and one was selected for the final test version on the basis of our pilot study 
with 20 PD patients and 30 control subjects and an analysis of the tasks’ sensitivities and 
specificities. In this latter spatial imagery task which contains three items (after item selection 
out of six original items) half-masked squares with dot patterns are presented and the subject 
is expected to find the pattern which emerges on removing the mask (see Fig. 1). Items have 
to be evaluated in the given alignment i.e. they should not be rotated mentally. The maximal 
raw score is 3.  
 
(4) Working memory and attention task: Working memory can be defined as the ability to 
hold and manipulate information by means of one controlling system, the „central executive“, 
and additional phonological and visuospatial „slave“ systems, and its concept is closely linked 
to the concept of attention [21]. Many studies report working memory dysfunction in PD 
patients in the verbal (e.g. [22,23]) and nonverbal domain [24] and deficits in attention [25]. 
Several tests serve to assess working memory and attention. In our pilot study we used two 
tasks. In the letter–number–sorting task as used by Gold et al. [33] letters and numbers are 
read aloud in a random order and the patient has to sort letters and numbers separately in their 
systematic order. In the more simple but still sensitive variant of the task which we finally 
selected due to results of our pilot study only rows of numbers are presented in a random 
order (e.g. „7–2–8–6“), and the subject is expected to repeat these numbers in a systematic 
order („2–6–7–8“). The number of items in the largest row correctly repeated is analyzed. The 
maximal score is 6.  
 
Mood questionnaire: We aimed at providing a short and easy assessment of depressive 
symptoms which are the most common nonmotor symptoms of PD and are a significant cause 
of functional impairment in these patients [5]. We designed a condensed, mood-related 
questionnaire with three questions representing central aspects of depressive mood (mood, 
interest, drive). On a four-stage rating scale the subjects evaluate whether the statements are 
correct (4 points), mostly correct, mostly incorrect, or incorrect (0 points). The maximal score 
is 9.  
 
2.2. Subjects  
 
One hundred and eight control subjects (control group (CG)) classified as cognitively 
unimpaired by trained neuropsychologists and with a clinical dementia rating scale score [26] 
of 0 were included. The control subjects were recruited by placing an advertisement in a local 
newspaper and a placard in the University Clinic Cologne. Additionally, 124 patients with 
idiopathic PD (criteria according to the UK Parkinson’s Disease Society Brain Bank criteria) 
[27] were recruited from three specialized Parkinson clinics in Germany. All patients were 
examined and diagnosed by movement disorders specialists (see Table 1 for Hoehn and Yahr 
stages). Patients were stratified into clinical PD subtypes (tremor-dominant, equivalent, and 
akinetic-rigid type) according to the leading clinical symptomatology. The patients were also 
subdivided into three groups according to their cognitive state: 38 PD patients were diagnosed 
to have dementia (PDD group) according to DSM-IV criteria [28], 40 patients were classified 
as having mild cognitive disorder (PD-MCD group) according to ICD-10 [29], and in 46 
patients no cognitive impairment was observed (PD group) (Table 1). Despite considerable 
discussion with regard to the validity of the ICD-10 diagnosis of mild cognitive disorder 
(MCD) [30] this concept—and not the frequently used concept of mild cognitive impairment 
(MCI) [31]—was chosen because MCD (1) requires MCI but is not focused on memory 
dysfunction, well applicable for PD patients, (2) does not demand subjective memory 
complaints which are not always present in PD patients with mild cognitive dysfunctions, and 
(3) requires a cerebral disease, damage or dysfunction, or systemic physical disorder as a 
cause of cognitive dysfunction, which is the case for PD patients.  
 
All patients underwent elaborate neuropsychological testing by neuropsychologists with 
different test instruments in the three Parkinson clinics. The evaluation of the cognitive state 
was made by expert rating on the basis of the results of neuropsychological testing. The 
PANDA test results were not considered for dementia diagnosis. All procedures were carried 
out with an adequate understanding and written consent of the subjects.  
 
2.3. Neuropsychological testing  
 
All subjects were tested with the PANDA (a final test version can be obtained from the 
corresponding author). Additionally, the PD patients and also a subpopulation of the CG (n = 
50) were examined with the MMSE [32,33] and the Beck Depression Inventory (BDI) [34]. 
The patients were tested being „on“.  
 
2.4. Statistical analysis  
 
All analyses were carried out using the Statistical Package for the Social Sciences (SPSS) 
version 14 for Windows (Release 14.0.2, SPSS Inc., Chicago). Non-parametric tests were 
used to check for differences in distribution (chi-square test) and for analyses of ordinal scale 
data (Kruskal–Wallis and Mann–Whitney U test). Otherwise, parametric methods were used 
after checking for statistical normal distribution of the data with the Kolmogorov–Smirnov 
test, i.e. univariate analysis of variance (ANOVA) with post hoc Scheffé tests and 
multivariate analyses of covariance (MANCOVA). Multiple comparisons were calculated 
with Bonferroni adjustment. ROC analyses were performed to define sensitivities and 
specificities of test scores, optimal cut-off scores, and areas under the curve. Results are 
indicated as means with standard deviations (SD), or with medians and ranges.  
 
3. Results  
 
3.1. Characteristics of study groups  
 
Univariate variance analysis revealed significant effects for the factors age (F(3,228) = 21.1, 
p<0.001, partial η2 = 0.218) and education (F(3,228) = 10.8, p<0.001, partial η2 = 0.125). 
Both the CG and the PD group were significantly younger and had more years of education 
than the PD-MCD and PDD groups. There were no differences in the distribution of gender. 
The PD subgroups were comparable regarding disease duration, but there was a significant 
main effect for the Hoehn and Yahr stage (Kruskal–Wallis test, chi-scquare = 18.5, p<0.001) 
in that the PDD patients had higher scores than the PD and the PD-MCD group (see Table 1).  
 
3.2. MMSE and BDI  
 
The MMSE scores of all study groups and corresponding statistical results are listed in Table 
1. A MANCOVA was performed. Age and education for which main group effects had been 
demonstrated (see Table 1) were included as covariates. There was a significant main effect 
for the factor study group (F(3,168) = 49.9, p<0.001, partial η2 = 0.471). Furthermore, there 
was an effect for education (F(1,168) = 7.7, p<0.05, partial η2 = 0.044), but not for age. 
Group comparisons revealed that the PDD group scored significantly lower than all other 
study groups (p<0.001). Furthermore group differences were observed for comparison 
between CG and PD-MCD and PD and PD-MCD (p<0.05). No other differences were 
observed. When the MMSE0s original cut-off score for dementia of 24/25 points was used, 
the instrument had a specificity of 100% and a sensitivity of 63%. With a higher cut-off of 
25/26 which has been proposed to improve the instrument0s diagnostic accuracy to detect 
dementia [35] the specificity remained high at 98%, but the sensitivity was still relatively low 
at 68%. When both the PDD and the PD-MCD patients were included in the analysis with the 
higher cutoff score in order to determine the MMSE’s general capability to detect cognitive 
impairment (including mild dysfunction), the sensitivity was only 45%. Contrasting PD and 
PDD patients with a cut-off score of 25/26 points, the specificity was 100%, and the 
sensitivity was 68%. An analysis of all PD patients showed that only 28% of the whole PD 
group had MMSE scores below this cut-off, although 63% were actually impaired (either PD-
MCD or PDD).  
 
The BDI scores of the study groups and corresponding statistical results are listed in Table 1. 
In the MANCOVA controlled for the covariates age and education there was a significant 
main effect for the factor study group (F(3,168) = 9.0, p<0.001, partial η2 = 0.139). No effects 
for age or education were observed. Again, the PDD groups differed from all other study 
groups in that they had higher depression scores (p<0.01–p<0.001) and PD-MCD patients 
showed higher depression scores as compared to CG (p<0.01). No other group differences 
were observed. In total, 39% of the PD group had BDI scores above the cut-off score for mild 
to moderate depressive symptoms (11 points or above).  
 
3.3. PANDA raw scores  
 
The raw scores of all groups are demonstrated in Fig. 2. To test for group differences in the 
performance of the PANDA subtests a MANCOVA was calculated with age and education as 
covariates. This analysis showed significant main effects for the factor study group for all 
PANDA subtests (F(3,226) = between 17.0 and 44.6, all p<0.001, partial η2 between 0.184 
and 0.372). There were effects for age in all cognitive PANDA subtests (F(1,226) between 4.3 
and 36.2, p between 0.05 and 0.001, partial η2 between 0.019 and 0.138). No effects of 
education were observed. On a single comparison level using Bonferroni adjustment, the only 
significant differences between the CG and the PD group were revealed in the verbal fluency 
and spatial imagery tasks (p<0.05). Both the CG and the PD group scored higher than the PD-
MCD and the PDD patients in all subtests (p<0.05–p<0.001 for all group comparisons). The 
PD-MCD patients reached higher scores than the PDD group in all subtests except for the 
mental rotation task (all p<0.001, p<0.05 only for the delayed recall).  
 
3.4. Transformation of raw scores, determination of the test score, and interpretation of the 
PANDA  
 
To receive a meaningful PANDA total score, transformation algorithms for the raw scores 
had to be defined. First, the verbal fluency task does not have a maximum raw score so that 
some form of transformation is necessary. Second, in order to receive a highly sensitive 
instrument the subtests should contribute to the total score depending on their actual 
importance, that is their sensitivity, and not depending on their maximum raw scores. For 
example, in the word pair associate learning task of the PANDA the maximum score is 12 for 
the immediate recall and 4 for the delayed recall. However, the delayed recall is a better 
indicator for cognitive deterioration. Third, the total score should be independent of 
sociodemographic effects; an age correction is required.  
 
A maximum transformed score of 30 was arbitrarily determined for the PANDA. 
Classification rates of the subtests were analyzed and revealed that the verbal fluency task and 
the delayed recall condition of the word pair associate learning task obtained the highest 
sensitivity rates (more than 70%) and that the mental rotation task and the immediate recall of 
the pair associate learning task were least sensitive (both less than 65%). To account for these 
differences, the verbal fluency task and the delayed recall were given a maximum of 7 
transformed points, the working memory and attention task received 6, and the spatial 
imagery and immediate recall of the paired associate learning task received a maximum of 5 
transformed points (30 points in total).  
 
The second step was to find concrete transformation algorithms of the raw scores on the basis 
of the CG data and under consideration of the age effects. As such, all algorithms, except for 
the working memory and attention task (no age effect), were defined for two age groups up to 
59 and 60 years or older, respectively. The mean raw score of the corresponding CG (young 
group, n = 51, mean age 52.2 [SD = 6.0] years and older group, n = 57, mean age 67.5 [SD = 
6.3] years) was given the highest transformed score; scores of at least two SD below were 
given the lowest transformed score (i.e. 0 points for a percentile equivalent of 2) and the 
values in between assigned accordingly. Few exceptions were made depending on the 
distribution of the scores.  
 
For the user of the test the transformation procedure is simple. Age-dependant tables for each 
subtest which display the range of possible raw scores and their corresponding transformed 
scores are provided. For the final PANDA total score the transformed scores have to be 
summed up.  
 
With this procedure the mean total PANDA score was 23.6 (SD = 5.4) in the CG (purified 
from age effects), 22.7 (SD = 4.3) for the PD patients, 15.8 (SD = 5.0) for the PD-MCD 
group, and 7.9 (SD = 5.6) for the PDD group. The transformed scores for all subtests and the 
total PANDA test scores for the study groups are demonstrated in Fig. 3. In a variance 
analysis significant main effects were found for all transformed subtest scores and the total 
score for the subtests (F(3,226) = between 15.8 and 45.5, all p<0.001, partial η2 = between 
0.174 and 0.376) and for the total score (F(3,226) = 71.2, p<0.001, partial η2 = 0.486). There 
were no significant differences between the CG and the PD group, and both the CG and PD 
group showed superior performance compared to the PD-MCD and the PDD patients in all 
transformed scores (p<0.001 for all group comparisons, except for one significant contrast of 
the PD versus PD-MCD group in spatial imagery with p<0.05). All transformed scores of the 
PDMCD group except for the spatial imagery task were higher than those of the PDD patients 
(p<0.001).  
 
In a further step, a cut-off score for cognitive impairment was defined. In accordance with 
established procedures [10], cognitive dysfunction was determined on the basis of the results 
of the CG, and all scores within one SD below the mean score were regarded as „age 
adequate“ (≥18 points), and scores below 1.5 SD of CG data were determined as indicating 
clear cognitive disturbance, that is dementia (≤14 points). Scores in between one and 1.5 SD 
below mean CG data were defined to reflect subtle cognitive disturbance (15–17 points). 
ROC analysis further supported the cut-off score for cognitive impairment of 17/18 points: 
with this cut-off the PANDA has a specificity of 91% and a sensitivity of 90% when 
including only the PDD patients, and it has a sensitivity of 77% when both the PD-MCD and 
the PDD patients are included as a cognitively impaired group. The areas under the curve are 
0.917 and 0.708, respectively. The „specificity“ for the PD patients that were not cognitively 
impaired was 89% (i.e. these patients had scores of 18 points or above). With regard to the 
lower cut-off score of 14/15 points, 84% of the PDD patients had PANDA scores below this 
cut-off. Finally, of all PD patients 52% subjects were classified to be cognitively impaired 
(63% were impaired according to the expert rating).  
 
In 30 control subjects who were retested after 6 months, the retest reliability for the PANDA 
cognition part was r = 0.93 (p<0.001). There was no significant change of the answers in the 
mood questionnaire (p = 0.253). The interrater reliability tested in a subpopulation of 50 PD 
patients was r = 0.95 (p<0.001). The cognition part of the PANDA correlates with the MMSE 
with r = 0.75 for all subjects, r = 0.48 for the CG, r = 0.73 for the PDD patients, and r = 0.76 
for the PD patients (all p<0.001). In all PD patients, the PANDA transformed total score of 
the cognition part correlated significantly with the BDI (r = -0.34, p = 0.001).  
 
The median of the mood questionnaire (max. 9) was 2 (range 0–6) in the CG and 3 (range 0–
9) in the PD group. A ROC analysis was performed with all PD patients and using the BDI 
classification of patients with or without depressive symptoms (cut-off score of 10/11) as a 
gold standard [39]. This analysis revealed an optimal cut-off score of 4 points for the PANDA 
mood questionnaire, showing a good balance of sensitivity (80%) and specificity (92%). For 
the whole PD group (all subgroups), a significant correlation of the PANDA mood 
questionnaire and the BDI (rho = 0.64, p<0.001) was observed. The correlations of the 
PANDA mood questionnaire and the BDI in the study subgroups were rho = 0.65 (p<0.001) 
in the PD group, rho = 0.48 (p<0.01) in the PD-MCD group, and rho = 0.68 (p<0.001) in the 
PDD group. The PANDA mood questionnaire correlated with the PANDA cognition 
transformed total score with rho = -0.29 (p<0.001) for all PD patients.  
 
4. Discussion  
 
A detection of cognitive impairment early in the course of PD is useful for the patient, 
caregiver, and physician to plan future treatment. For example, recent studies suggest that 
cholinesterase inhibitors may be effective in the treatment of dementia in PD [36]. Our study 
demonstrates that the new cognitive screening instrument PANDA is an appropriate tool to 
detect cognitive dysfunction and dementia in Parkinson patients in clinical settings and for 
general practitioners. It is short (8–10 min), easy to administer, and, following score 
transformation, is independent of age and education (although education effects might exist in 
very low-educated populations and are subject to further investigation). With its high 
construct validity, objectivity, and retest and inter-rater reliability the instrument fulfills 
relevant psychometric criteria. Most importantly, it has high specificity and high sensitivity. It 
should be emphasized though that this validation study has been performed in a sample of 
Parkinson patients and that the reported sensitivity and specificity refer to this specific patient 
group and not a more general group of older people with possible cognitive dysfunction, or 
patients with other forms of dementia (e.g. Alzheimer’s disease). The PANDA has been 
developed for PD patients and can be used when PD has been diagnosed. Finally, an 
important characteristic is the PANDA’s well-balanced assessment of cognitive domains 
typically affected in PD patients i.e. executive functions, memory (strategic encoding and 
retrieval) and working memory and attention, as well as visuospatial functions. This balance 
is probably responsible for the PANDA’s high sensitivity even for MCD in PD patients. 
Future studies will have to demonstrate the sensitivity for other frequently used concepts such 
as MCI in its original form [31] or in later defined subtypes (amnestic versus nonamnestic 
MCI) [37].  
 
The PANDA thus has some advantages compared to existing other cognitive screening 
instruments. The MMSE [32] is probably the most frequently used screening tool. However, it 
has been criticized for lack of sensitivity [38], and education and age dependency [39]. Age-
specific norms for the MMSE have been defined [40] but are not integrated in the tool’s 
common test versions and are thus rarely used. Also, the MMSE (and other instruments such 
as MIS [10]) has been designed for „cortical“ types of dementia which differ from 
„subcortical“ dementia [41] and does not, for example, assess executive functions. 
Consequently, our data demonstrate that the MMSE’s sensitivity to detect cognitive 
impairment in PD patients is much lower than that of the PANDA. The ACE [6] comprises 
basic items of the MMSE and additional short subtests including language, verbal fluency 
(and thus executive), and visuospatial measures. To our knowledge there are no reports of the 
use of the ACE in patients with idiopathic PD, and in fact its item composition again may not 
grasp PD patients0 typical cognitive deficits. Furthermore, performance in the 
visuoconstructive tasks (copying a two and a three-dimensional figure) may confound with 
motor dysfunction in these patients. The Mattis dementia rating scale [42] evaluates attention, 
perseveration, praxis, abstraction, and verbal and nonverbal recent memory. It is frequently 
used to indicate dementia in patients with PD, but is not a proper tool to detect mild cognitive 
dysfunction. The Seven Minute Screen [7] has been proved to be sensitive in different types 
of dementia and also MCI but to the knowledge of the authors has not been specifically tested 
in PD patients. Performance in this tool depends on age, education and gender, and the 
administration time may be higher than its name suggests [43]. The new CAMCOG-R battery 
[44] added two new subtests of executive functions—ideational fluency and visual 
reasoning— but according to a study by Leeds et al. [45] these tasks seem to offer little 
advantage, and there are concerns about their construct validity. Furthermore, the scale seems 
to be inappropriate as a screening tool, due to an administration time of 23 min. Finally, the 
SCOPA-COG presented by Marinus and colleagues [16] has been developed as a reliable and 
valid test battery specifically designed to assess cognitive deficits in PD patients. This tool 
was not designed as a screening tool or a diagnostic instrument but instead is intended for 
comparing groups in research settings. In summary, the cognitive part of the PANDA fills the 
gap of an appropriate screening instrument to detect cognitive dysfunctions in PD patients in 
clinical settings and for general practitioners.  
 
A special further feature of the PANDA is the fact that it accounts for the most frequent 
neuropsychiatric symptom in PD patients, namely depression. The mood questionnaire 
corresponds well with the results in the BDI as a „gold“ standard and can thus be regarded as 
a valid but short and easy tool for the clinician to objectify possible depressive symptoms. 
Depression may be present in up to half of the PD patients and is of high clinical relevance 
[5]. Depression can adversely affect health-related quality of life and can have a significant 
impact on the patient0s cognitive functions, especially in the domains of memory and 
attention [46]. Our data also demonstrate this relationship. Thus, when using the PANDA one 
has to be aware of the fact that cognitive dysfunctions as elicited by this brief instrument may 
at least in part be confounded with depressive symptoms—and may be modulated by their 
treatment. However, a decision on whether cognitive dysfunctions are secondarily caused by 
depression or constitute primary symptoms of the disease is a difficult question per se and can 
certainly not be answered by using a short screening instrument.  
 
In general it must be emphasized that screening tools are helpful in identifying possible 
patients with cognitive disturbance. However, they do not replace an elaborate 
neuropsychological test battery. Further studies with larger patient samples—both demented 
and non-demented—are desirable to confirm the discrimination rates that were determined on 
the basis of our data base. Additionally, more research is required that elucidates the relation 
of the PANDA scores with other neuropsychological test instruments [47]. Furthermore, 
effects of clinical parameters in PD, such as disease duration and severity, on performance in 
the PANDA should be examined. Finally, further studies must show the PANDA’s capability 
to reflect treatment effects in the form of cognitive training or cognitive enhancers.   
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